BioSpace News Archive

PierianDx, the global leader in clinical genomics knowledge, announced that it has partnered with Biodesix to provide its interpretation technology platform for use with the Biodesix newly launched GeneStrat NGS™ genomic test, a blood-based tumor profiling test to detect actionable mutations in patients with non-small cell lung cancer.

The International Journal of Digital Health has published the 24-month clinical study results showing a sustained and significantly improved HbA1c result for people with diabetes utilizing the Pops Self-care Platform for self-management.

Neurophth Therapeutics, Inc., today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application on the in-vivo gene replacement therapy NR082 (rAAV2- ND4 ).

Panavance Therapeutics Inc. (“Panavance”) announces an abstract and poster at ASCO Gastrointestinal Cancers Symposium, January 20-22, 2022, in San Francisco, “A Phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma,” (authors: Dr. Anup Kasi and Dr. José Iglesias, Poster TPS620).

Engineers and researchers in the Institute of Bioelectronic Medicine at The Feinstein Institutes for Medical Research have developed a novel fully-implantable wireless bidirectional vagus nerve stimulation (VNS) and sensing device for mice.

Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will host a virtual presentation of its poster at the American Society of Clinical Oncology’s (ASCO) Gastrointestinal Cancers Symposium being held from January 20-22, 2022, at the Moscone West Building in San Francisco, CA.

On the heels of recent news of FDA clearance for Colibri™, automated colony picking instrument for identification and antimicrobial susceptibility testing in clinical Microbiology, today COPAN announced the North American launch of PhenoMATRIX® TAG.

Rising inclination towards continuous manufacturing, rapidly growing biologics market, and increasing growth opportunities in biopharmaceutical sector are key factors driving market growth.

The global mice model market size is expected to reach USD 2.49 Billion by 2028 registering a CAGR of 6.6% over the forecast period, according to a latest report by Reports and Data.

Rising demand for biologics, increasing drug approvals and launch of new drugs, and rising prevalence of chronic diseases across the globe are key factors expected to drive market growth.